Now available EPYSQLI

EPYSQLI (eculizumab-aagh) is biosimilar to SOLIRIS (eculizumab).
EPYSQLI is a complement inhibitor indicated for:

• the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
• the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use:
EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive.

Please see full prescribing information here.

PLEASE NOTE: To access this EPYSQLI product you must enroll and become certified in the EPYSQLI REMS. EPYSQLI REMS requires 24 to 48 hours from customer time of completed registration to be added to the approved listing. Please have the customer contact the EPYSQLI REMS Program if they have any questions or issues.

EPYSQLI REMS Contact: 1-866-318-8744